ERBB2 and breast carcinoma: Apart from CDK4/6, CDK2 is also involved in cell cycle progression through the G1, S, and G2 phases, and aberrant CDK2 activation is associated with CDK4/6 inhibitors in HER2-responsive breast cancers [29].